FDA guidance on drug names expected in "near future," agency's Woodcock says.
This article was originally published in The Tan Sheet
Executive Summary
FDA GUIDANCE ON PHARMACEUTICAL DRUG NAMES EXPECTED IN "NEAR FUTURE," Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Minimizing Medical Product Errors conference in Bethesda, Md. Jan. 8. The guidance will outline principles for the pharmaceutical industry "when selecting proprietary names," Woodcock said, because "as more and more drugs get on the market, it has become an increasing problem in developing proprietary names that cannot, either written or verbally, be confused with another drug."